Researchers at the University of Pittsburgh have identified Cytochrome c oxidase subunit 4 isoform 1 (Cox4i1) as a novel molecular target of metformin, a widely used antihyperglycemic agent. This discovery opens new avenues for the development of first-in-class small molecules for the treatment of diabetes, potentially revolutionizing diabetes therapy. The identification of Cox4i1 as a target could lead to more specific and efficacious treatments for both Type 1 and Type 2 diabetes.